Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China; School of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan, China.
Department of Stomatology, Xintai Hospital of Traditional Chinese Medicine, Taian, China.
Br J Oral Maxillofac Surg. 2021 Jun;59(5):503-510. doi: 10.1016/j.bjoms.2020.08.049. Epub 2020 Aug 19.
The object of this paper was to explore the feasibility and advantages of endoscope-assisted parotid tumour resection. Three databases (PubMed, Web of Science, and Cochrane) were used to search for all related randomised controlled trials or controlled trials (up to November 2019). The key parameters for assessment included 'Endoscope', 'Endoscopes', 'Cancer of Parotid', and 'Parotid Cancer'. To evaluate the feasibility and advantages of endoscope-assisted resection of parotid tumours, the data for each parameter were pooled, based on patients who received endoscope-assisted surgery and those who received conventional surgery. This meta-analysis included seven studies, involving 170 patients in the endoscopy group and 270 patients in the control group. The analysis using the pooled data showed that there were no significant differences in the operating times between the two groups; however, the endoscopy group had significantly shorter incisions and less intraoperative bleeding. In addition, the patients who received endoscope-assisted surgery had lower incidences of temporary facial paralysis and Frey's syndrome after surgery. Patients in the endoscopy group had greater postoperative satisfaction. Endoscope-assisted parotid tumour resection results in only a small, concealed incision wound and fewer postoperative complications. Therefore, it is promising for the surgical treatment of parotid tumours.
本文旨在探讨内镜辅助腮腺肿瘤切除术的可行性和优势。我们检索了三个数据库（PubMed、Web of Science 和 Cochrane），以查找所有相关的随机对照试验或对照试验（截至 2019 年 11 月）。评估的关键参数包括“内镜”、“内镜”、“腮腺癌”和“腮腺肿瘤”。为了评估内镜辅助腮腺肿瘤切除术的可行性和优势，我们根据接受内镜辅助手术和常规手术的患者，对每个参数的数据进行了汇总。本荟萃分析纳入了 7 项研究，内镜组 170 例，对照组 270 例。汇总数据的分析显示，两组的手术时间无显著差异；然而，内镜组的切口更短，术中出血量更少。此外，接受内镜辅助手术的患者术后暂时性面瘫和 Frey 综合征的发生率较低。内镜组患者术后满意度更高。内镜辅助腮腺肿瘤切除术仅导致小而隐蔽的切口伤口和更少的术后并发症。因此，它有望成为腮腺肿瘤的一种手术治疗方法。
